Dose Escalation Versus Standard in Laryngopharyngeal Cancers

NACompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

December 31, 2022

Study Completion Date

December 31, 2022

Conditions
Malignant Neoplasm of Oropharynx Stage IIIMalignant Neoplasm of Larynx Stage IIIMalignant Neoplasm of Hypopharynx Stage IIIMalignant Neoplasm of Oropharynx Stage IVaMalignant Neoplasm of Oropharynx Stage IVbMalignant Neoplasm of Larynx Stage IVMalignant Neoplasm of Hypopharynx Stage IVaMalignant Neoplasm of Hypopharynx Stage IVb
Interventions
RADIATION

Escalated Dose

"Boost Target Volume (BTV): The PET CT GTV (thresholding at 40% of SUV max) with a 3mm margin will form the BTV.~CTV1: A 3mm area around the BTV avid primary or 2mm area around the node will form the CTV1.~CTV 2: This (CTV 2) includes the area around the primary or nodal levels at risk of harbouring microscopic primary or microscopic nodal metastatic disease and not already included in CTV1.~Planning Target Volume: PTV - A margin of 5mm will be added to each of the CTV to obtain the PTV.~BTV receives 73.5Gy in 30 fractions. PTV 1 receives 63Gy in 30 fractions. PTV 2 receives 54 Gy in 30 fractions.~All patients receive concurrent platinum chemotherapy."

RADIATION

Standard Dose

"CTV 1 includes 6mm isotropic margin around the entire PET-CT avid (thresholding at 40% of SUV max) larynx/ hypopharynx /oropharynx and 5mm isotropic margin around nodes.~CTV 2: This (CTV 2) includes the area around the primary or nodal levels at risk of harbouring microscopic primary or microscopic nodal involvement, or at risk nodal areas, and not already included in CTV1.~Planning Target Volume: PTV - A margin of 5mm will be added to each of the CTV to obtain the PTV.~PTV 1 receives 66Gy in 30 fractions. PTV 2 receives 54 Gy in 30 fractions.~All patients receive concurrent platinum chemotherapy."

Trial Locations (1)

700156

Tata Medical Centre, Kolkata

All Listed Sponsors
lead

Tata Medical Center

OTHER

NCT02757222 - Dose Escalation Versus Standard in Laryngopharyngeal Cancers | Biotech Hunter | Biotech Hunter